What the FDA MAUDE and Recall Record Reveals About Topical Tissue Adhesive Failures: A Post-Market Evidence Map for Procurement and Supplier-Qualification Buyers

How Does the FDA Classify Topical Tissue Adhesives, and Who Holds the 36 MPN Clearances?

Topical tissue adhesives formulated from synthetic cyanoacrylate monomers (primarily 2-octyl cyanoacrylate and n-butyl cyanoacrylate) occupy a specific regulatory position under FDA rules ⁷. Codified under 21 CFR 878.4010 ⁴, product code MPN (Tissue Adhesive for the Topical Approximation of Skin) designates Class II medical devices intended solely for topical closure of easily approximated skin edges from surgical incisions and simple traumatic lacerations.

Historically, topical cyanoacrylate adhesives were regulated as Class III premarket approval (PMA) devices. The pioneer product, Dermabond (2-octyl cyanoacrylate developed by Closure Medical Corp and commercialized by Ethicon), received PMA approval under P960052 on August 26, 1998 ¹. Following decade-long clinical experience and extensive safety data, the FDA issued a final reclassification order on May 5, 2008 (Docket FDA-2006-P-0140 / 73 FR 24832), reclassifying topical tissue adhesives from Class III to Class II subject to special controls ³. Crucially, non-topical cyanoacrylate applications—such as internal vascular embolization, ophthalmic sealing, or deep tissue approximation—remain high-risk Class III devices.

Under the Class II 510(k) pathway, manufacturers must demonstrate substantial equivalence to a predicate device while complying with the FDA Class II Special Controls Guidance ². An inspection of the FDA 510(k) database shows 36 total clearances for product code MPN ⁸. The clearance landscape is concentrated among a select group of specialized medical-polymer manufacturers:

Geographically, the 36 510(k) clearances are held predominantly by manufacturers in the United States (25 clearances) and the United Kingdom (8 clearances), reflecting the specialized chemical manufacturing, aseptic filling, and moisture-barrier packaging infrastructure required for monomeric cyanoacrylates. For procurement teams evaluating suppliers, understanding how pre-market chemistry translates into post-market reliability is critical. A detailed review of monomer formulation choices, biocompatibility, and lot acceptance is available in our companion guide on medical cyanoacrylate adhesive supplier qualification.

What Do 1,155 MAUDE Reports Reveal About the Dominant Skin-Closure Adhesive Failure Modes?

To analyze real-world clinical complications, we extracted all device-level records for product code MPN from the FDA Manufacturer and User Facility Device Experience (MAUDE) database for the receive years 2020 through 2025 ⁵. Over this 6-year surveillance window, the database registered 1,155 device-level rows representing 1,143 unique medical device reports (MDRs).

A primary finding of this surveillance analysis is the distribution of event types: 843 reports (72.9%) are classified as Injury, 310 reports (26.8%) as Device Malfunction, 1 report (0.1%) as Death, and 1 report (0.1%) as Other. The report source mix is dominated by mandatory manufacturer filings: 1,059 manufacturer reports (91.7%), 77 voluntary user reports (6.7%), 16 user facility reports (1.4%), and 3 distributor reports (0.3%). A large share of the malfunction reports carry a 'No Clinical Signs, Symptoms or Conditions' coding, reflecting routine lot-complaint notifications rather than patient harm. Note that the single Death report involved an event coded in clinical proximity to adhesive application; MAUDE reporting guidance explicitly states that filing a report does not constitute an admission of device causation.

Categorizing the specific patient problem codes across the 1,155 MAUDE rows reveals six dominant failure modes ⁹:

• Skin Inflammation & Local Irritation (34.7% / 401 mentions): Acute erythema, localized edema, persistent itching, and contact dermatitis at the application site.
• Rash, Blistering & Vesicle Formation (17.7% / 205 mentions): Contact bullous dermatitis, epidermal blistering, and wheal formation surrounding the adhesive film.
• Hypersensitivity & Allergic Reaction (14.4% / 166 mentions): Type IV delayed-type hypersensitivity triggered by cyanoacrylate monomers or breakdown products (formaldehyde/cyanoacetate).
• Wound Infection & Cellulitis (10.0% / 116 mentions): Surgical site infection, purulent exudate beneath the adhesive, or localized cellulitis requiring topical or systemic antibiotics.
• Wound Dehiscence & Separation (8.2% / 95 mentions): Premature sloughing or adhesive fracture leading to separation of approximated skin edges.
• Tissue Damage, Necrosis & Chemical Burn (5.6% / 65 mentions): Thermal or chemical epidermal damage caused by rapid monomer polymerization exotherm, especially when contacting cotton gauze.

In terms of manufacturer concentration, Ethicon (Dermabond / Dermabond Advanced / Dermabond NX) accounts for 893 of 1,155 rows (77.3%). Advanced Medical Solutions (LiquiBand family) accounts for 129 rows (11.2%), B. Braun / Aesculap (Histoacryl) for 33 rows (2.9%), Chemence Medical (Exofin) for 30 rows (2.6%), and Medline for 8 rows (0.7%). This concentration reflects commercial market penetration and institutional reporting practices rather than higher intrinsic product risk. As seen in our parallel analyses of circumcision devices, endovenous laser fibers, and NPWT pumps, market leaders absorb the vast majority of mandatory surveillance reporting.

What Do the Two MPN Recalls Reveal About Sterility, Packaging and Storage Controls?

In sharp contrast to the 1,155 MAUDE device records, querying the FDA Medical Device Recall database yields exactly two recalls for product code MPN ⁶. Examining these two enforcement events provides valuable diagnostic insight into manufacturer quality control failures.

Analyzing why product code MPN exhibits 1,155 MAUDE reports but only 2 recalls is crucial for quality assurance directors. The vast majority of MAUDE injury filings stem from patient-specific hypersensitivity, application on high-tension wounds, or improper thickness during application—factors tied to clinical practice and intrinsic monomer chemistry rather than batch manufacturing defects. Conversely, the two recalls represent systemic failures in sterile barrier packaging validation and cold-chain climate control.

The contrast between high MAUDE injury reports and low recall counts demonstrates that topical tissue adhesive risk is driven by chemistry and usage factors rather than frequent batch manufacturing defects. Procurement due diligence must therefore focus on supplier packaging process control and temperature stability validation.— VEMERIX Quality & Regulatory Engineering Group

How Do MAUDE Failure Modes Map to the FDA Reclassification Risk Table and the Cochrane Dehiscence Evidence?

When the FDA reclassified topical tissue adhesives under Docket FDA-2006-P-0140 (73 FR 24832), CDRH established a comprehensive risk-and-mitigation matrix ³. Comparing FDA's six identified risks against observed MAUDE failure categories and systematic review evidence demonstrates remarkable alignment:

The clinical evidence regarding wound dehiscence is particularly instructive. A Cochrane systematic review of 33 randomized controlled trials (2,793 participants) comparing tissue adhesives to conventional sutures for surgical incision closure found low-quality evidence that sutures significantly reduce the risk of wound dehiscence (Risk Ratio 3.35, 95% CI 1.53 to 7.33) ¹⁰. The Number Needed to Treat for an additional Harmful outcome (NNH) was 43. Conversely, the Cochrane review found no evidence of a difference in surgical site infection rates between tissue adhesives and sutures. This clinical trial finding is directionally consistent with our MAUDE surveillance observation, where dehiscence represents 8.2% of reported device rows.

Chemical burns represent another high-severity failure mode. When liquid cyanoacrylate monomer comes into contact with cotton gauze or cellulose materials, the hydroxyl groups in cellulose act as a potent catalyst, accelerating polymerization and generating intense exotherm with surface temperatures exceeding 75°C ¹³. This thermal reaction can inflict full-thickness chemical burns. Procurement specs must mandate clear clinical warnings forbidding cotton swab contact during application.

How Should Procurement Teams Convert Surveillance Evidence Into Tissue-Adhesive Tender and Incoming-Inspection Specifications?

Hospital procurement committees, tender boards, and medical-device distributors should translate these regulatory and post-market findings into six concrete technical requirements:

1. Monomer Purity and Viscosity Control: Require high-purity monomer (> 98.5% 2-octyl or n-butyl cyanoacrylate) with verified viscosity. High-viscosity or thixotropic formulations prevent monomer runoff into eyes or healthy skin.
2. Exotherm Temperature Cap (< 45°C): Require batch test data establishing that peak polymerization exotherm does not exceed 45°C when applied at recommended film thickness, eliminating chemical burn risk.
3. Container-Closure Integrity (CCI) & Dye Ingress Testing: To prevent packaging seal breaches (as seen in Recall Z-0953-2021), mandate ASTM F1929 dye penetration and bubble emission testing for all sterile blister packaging.
4. Thermal Excursion Stability & Accelerated Aging: To prevent premature curing from heat exposure (as seen in Recall Z-1788-2022), require real-time and accelerated shelf-life validation (ISO 11607 / ASTM F1980) confirming monomer stability up to 25°C or 30°C.
5. ISO 10993 Biocompatibility Suite: Require complete ISO 10993 testing—specifically ISO 10993-5 (cytotoxicity), ISO 10993-10 (irritation and skin sensitization), and residual monomer/formaldehyde limits.
6. Precision Single-Use Applicator Audit: Require applicator drop testing and tip security validation to prevent ampoule cracking or applicator tip detachment during intraoperative handling.

Integrating these requirements into distributor evaluations and hospital RFQ documents ensures comprehensive quality control. For a broader framework on post-market recall controls across disposable medical devices, consult our analysis of sterile medical device recall evidence maps.

Frequently Asked Questions About Topical Tissue Adhesive Safety and Sourcing

Q: Do 1,155 MAUDE reports mean topical tissue adhesives are unsafe, or that Dermabond is worse than alternatives?
No. FDA MAUDE data represents passive surveillance and does not provide denominator-adjusted incidence rates. Ethicon Dermabond's 77% report share reflects its dominant global market share and established hospital reporting infrastructure rather than elevated product risk. When used on appropriate low-tension wounds according to instructions for use (IFU), topical cyanoacrylates are safe and effective Class II devices.

Q: Is 2-octyl cyanoacrylate regulated differently than n-butyl cyanoacrylate by the FDA?
Both 2-octyl cyanoacrylate and n-butyl cyanoacrylate topical skin adhesives are classified under 21 CFR 878.4010 (product code MPN) as Class II devices requiring 510(k) clearance. Chemically, 2-octyl cyanoacrylate possesses a longer alkyl side chain, providing greater film flexibility and higher lap shear strength, whereas n-butyl cyanoacrylate cures faster with higher initial rigidity but lower film flexibility.

Q: Why are there so few recalls (only 2) despite 1,155 MAUDE reports for product code MPN?
Most MAUDE reports stem from local contact dermatitis, mild skin irritation, dehiscence due to wound tension, or routine lot-complaint malfunctions with no patient harm—events linked to patient sensitivity or clinical application technique rather than systemic defects. Recalls, by contrast, occur when a systematic manufacturing or packaging defect affects an entire production lot. The two MPN recalls involved sterile packaging seal integrity (Z-0953-2021) and environmental temperature excursions (Z-1788-2022).

Q: What lot-release acceptance tests should a buyer require for each batch of medical adhesive?
Buyers should require batch Certificates of Analysis (CoA) covering 5 key parameters: monomer purity percentage, viscosity (cPs), setting time on moisture substrate (seconds), lap shear bond strength (MPa), and sterile barrier pouch seal strength (N/15mm).

Q: Can a cyanoacrylate tissue adhesive cause a chemical burn, and what does the evidence show?
Yes. Chemical or thermal burns represent 5.6% of MAUDE failure mentions. The primary mechanism is exothermic polymerization heat released when liquid monomer contacts high-surface-area catalysts, particularly cotton gauze or cellulose swabs. IFUs must explicitly instruct clinicians to avoid cotton contact and apply thin, layered coats.

Where VEMERIX Cyanoacrylate Skin Adhesives Fit—and Where Due Diligence Begins

As part of its Wound & Skin perioperative portfolio, VEMERIX markets Medical Adhesive—a Class II cyanoacrylate skin adhesive designed for closure of small wounds, minor surgical incisions, and superficial lacerations. Formulated for fast setting and flexible film bonding, it serves as a suture-alternative for non-chronic wound management.

In accordance with VEMERIX editorial standards, supplier qualification must begin with rigorous due diligence. Healthcare procurement teams and distributor partners evaluating skin closure consumables should request complete technical documentation, including:

• Full ISO 10993 biocompatibility test reports (cytotoxicity, irritation, sensitization).
• Sterilization validation documentation (EO sterilization under ISO 11135, SAL 10⁻⁶).
• Accelerated aging and real-time shelf-life stability test packages (ISO 11607).
• Batch Certificate of Analysis (CoA) templates covering monomer purity, viscosity, setting time, and seal integrity.
• Sample packs for physical inspection, applicator actuation testing, and trial evaluation.

To explore technical specifications, request sample packs, or discuss OEM/distributor partnerships for VEMERIX skin closure consumables, visit the Medical Adhesive product page, inspect our Quality Systems documentation, or contact the VEMERIX international team.